JP2013504520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504520A5 JP2013504520A5 JP2012514010A JP2012514010A JP2013504520A5 JP 2013504520 A5 JP2013504520 A5 JP 2013504520A5 JP 2012514010 A JP2012514010 A JP 2012514010A JP 2012514010 A JP2012514010 A JP 2012514010A JP 2013504520 A5 JP2013504520 A5 JP 2013504520A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- alkyl
- hydrogen
- cyclo
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000004423 acyloxy group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 206010028116 Mucosal inflammation Diseases 0.000 claims 3
- 201000010927 Mucositis Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003057 platinum Chemical class 0.000 claims 2
- CTQWVWWSERVGET-HZPDHXFCSA-N 7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O CTQWVWWSERVGET-HZPDHXFCSA-N 0.000 claims 1
- SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 claims 1
- 206010061172 Gastrointestinal injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical group O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 1
- 229960001674 tegafur Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24301909P | 2009-09-16 | 2009-09-16 | |
| US61/243,019 | 2009-09-16 | ||
| PCT/JP2010/066619 WO2011034210A1 (en) | 2009-09-16 | 2010-09-16 | Pharmaceutical combination for treating tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002010A Division JP2016056191A (ja) | 2009-09-16 | 2016-01-07 | 腫瘍を処置するための医薬的組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504520A JP2013504520A (ja) | 2013-02-07 |
| JP2013504520A5 true JP2013504520A5 (enExample) | 2013-10-31 |
| JP5891168B2 JP5891168B2 (ja) | 2016-03-22 |
Family
ID=43730802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514010A Active JP5891168B2 (ja) | 2009-09-16 | 2010-09-16 | 腫瘍を処置するための医薬的組合せ |
| JP2016002010A Pending JP2016056191A (ja) | 2009-09-16 | 2016-01-07 | 腫瘍を処置するための医薬的組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002010A Pending JP2016056191A (ja) | 2009-09-16 | 2016-01-07 | 腫瘍を処置するための医薬的組合せ |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9084815B2 (enExample) |
| EP (1) | EP2477632A4 (enExample) |
| JP (2) | JP5891168B2 (enExample) |
| KR (1) | KR101760963B1 (enExample) |
| CN (2) | CN107050458A (enExample) |
| AR (1) | AR078182A1 (enExample) |
| AU (1) | AU2010296307B2 (enExample) |
| BR (1) | BR112012005896A2 (enExample) |
| CA (1) | CA2772314A1 (enExample) |
| IL (1) | IL218392A (enExample) |
| MX (1) | MX2012003188A (enExample) |
| NZ (1) | NZ598618A (enExample) |
| RU (2) | RU2577700C2 (enExample) |
| SG (2) | SG10201405467PA (enExample) |
| TW (1) | TWI535436B (enExample) |
| WO (1) | WO2011034210A1 (enExample) |
| ZA (1) | ZA201201894B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US20150099802A1 (en) * | 2013-10-03 | 2015-04-09 | Sucampo Ag | Selective tumor treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| TW249226B (enExample) | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| US5302617A (en) | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| ES2099736T3 (es) | 1990-04-27 | 1997-06-01 | R Tech Ueno Ltd | Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias. |
| US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
| US5438075A (en) * | 1993-03-30 | 1995-08-01 | Skubitz; Keith M. | Oral glutamine to reduce stomatitis |
| RU2071780C1 (ru) * | 1993-10-11 | 1997-01-20 | Научно-производственное предприятие "Фармэк" | Способ лечения медикаментозных эзофаго-гингиво-стоматитов |
| JPH0770054A (ja) | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| JP3187438B2 (ja) | 1996-06-10 | 2001-07-11 | 株式会社アールテック・ウエノ | エンドセリン拮抗剤 |
| NZ521464A (en) | 2000-03-24 | 2004-09-24 | Sucampo Ag | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| EP1641462B1 (en) * | 2003-07-03 | 2010-11-24 | Sucampo AG | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| BRPI0607084A2 (pt) | 2005-01-27 | 2009-08-04 | Sucampo Ag | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
-
2010
- 2010-09-15 US US12/882,794 patent/US9084815B2/en not_active Expired - Fee Related
- 2010-09-16 RU RU2012114771/15A patent/RU2577700C2/ru not_active IP Right Cessation
- 2010-09-16 BR BR112012005896A patent/BR112012005896A2/pt not_active IP Right Cessation
- 2010-09-16 KR KR1020127009499A patent/KR101760963B1/ko not_active Expired - Fee Related
- 2010-09-16 EP EP10817322.0A patent/EP2477632A4/en not_active Withdrawn
- 2010-09-16 SG SG10201405467PA patent/SG10201405467PA/en unknown
- 2010-09-16 SG SG2012018321A patent/SG179153A1/en unknown
- 2010-09-16 WO PCT/JP2010/066619 patent/WO2011034210A1/en not_active Ceased
- 2010-09-16 AR ARP100103379A patent/AR078182A1/es unknown
- 2010-09-16 NZ NZ598618A patent/NZ598618A/en not_active IP Right Cessation
- 2010-09-16 CN CN201611061998.1A patent/CN107050458A/zh active Pending
- 2010-09-16 CA CA2772314A patent/CA2772314A1/en not_active Abandoned
- 2010-09-16 AU AU2010296307A patent/AU2010296307B2/en not_active Ceased
- 2010-09-16 CN CN2010800410970A patent/CN102481302A/zh active Pending
- 2010-09-16 TW TW099131408A patent/TWI535436B/zh not_active IP Right Cessation
- 2010-09-16 RU RU2016103415A patent/RU2016103415A/ru not_active Application Discontinuation
- 2010-09-16 MX MX2012003188A patent/MX2012003188A/es active IP Right Grant
- 2010-09-16 JP JP2012514010A patent/JP5891168B2/ja active Active
-
2012
- 2012-02-29 IL IL218392A patent/IL218392A/en not_active IP Right Cessation
- 2012-03-14 ZA ZA2012/01894A patent/ZA201201894B/en unknown
-
2015
- 2015-06-15 US US14/739,242 patent/US20150272961A1/en not_active Abandoned
-
2016
- 2016-01-07 JP JP2016002010A patent/JP2016056191A/ja active Pending
- 2016-12-07 US US15/371,413 patent/US20170079986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503621A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2011517683A5 (enExample) | ||
| JP2010090149A5 (enExample) | ||
| JP2011527345A5 (enExample) | ||
| JP2004527567A5 (enExample) | ||
| JP2013519653A5 (enExample) | ||
| JP2012506443A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2014515407A5 (enExample) | ||
| JP2014511825A5 (enExample) | ||
| JP2006513232A5 (enExample) | ||
| JP2013504520A5 (enExample) | ||
| JP2012528186A5 (enExample) | ||
| JP2008528440A5 (enExample) | ||
| JP2014237711A5 (enExample) | ||
| JP2011509237A5 (enExample) | ||
| JP2014510022A5 (enExample) | ||
| JP2011500841A5 (enExample) | ||
| JP2014527048A5 (enExample) | ||
| JP2016528165A5 (enExample) | ||
| RU2010121882A (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
| RU2012114771A (ru) | Фармацевтическая комбинация для лечения опухоли | |
| JP2004538306A5 (enExample) |